This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $564,543 to Weill Medical College of Cornell University to conduct research on the role of the androgen receptor (AR) in prostate cancer. The research aims to determine the context that allows engagement of growth-suppressive AR transcriptional programs, establish the implications of oncogenic and growth-suppressive AR programs in human prostate cancer patients, and...
This federal Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) provides $632,906 in funding to Tulane University to conduct research on the role of RNA-binding by the androgen receptor (AR) in prostate cancer progression and therapeutic resistance. The 5-year project, beginning April 1, 2025, aims to elucidate how AR's interactions with pre-mRNA splicing factors contribute to the expression of genes critical for prostate cancer...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research at the Albert Einstein College of Medicine to investigate the non-autonomous role of androgen signaling in prostate tumorigenesis. The $535,334 award, active from January 1, 2025 to December 31, 2029, will test the central hypothesis that androgen signaling in prostatic GLI1-lineage cells acts as a tumor niche to promote prostate epithelial oncogenesis, tumor initiation,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The Washington University in St. Louis to support research aimed at overcoming resistance to second-generation androgen receptor (AR) antagonists in prostate cancer. The key objectives are to: Determine the mechanism by which the long non-coding RNA NXTAR is suppressed in castration-resistant prostate cancers (CRPCs). Synthesize PSMA-targeted nanoparticles loaded with...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program provides $539,633 in funding to the Albert Einstein College of Medicine to investigate the role of aberrant androgen receptor (AR) signaling in promoting prostate cancer development and progression, particularly in African American patients. The key objectives are to use new animal models and single-cell RNA sequencing of human prostate cancer samples to directly test the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Case Western Reserve University provides $606,869 in funding to investigate the mechanisms of androgen receptor inverse agonists in the treatment of advanced prostate cancer. The 5-year project aims to leverage sophisticated molecular biology and computational techniques to map the epigenetic mechanisms driving treatment-resistant metastatic castration-resistant prostate cancer (mCRPC). Key...
The federal Project Grant award R01CA299870, totaling $371,719.00, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The award, effective March 1, 2025 through February 28, 2030, supports research by The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, to investigate the role of the epigenetic modifier NSD2 in regulating the androgen receptor (AR)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,361 to Yale University to develop deep learning-based models for personalized treatment planning of PSMA radiopharmaceutical therapy (RPT) for prostate cancer. The research aims to utilize imaging data from PSMA-PET and PSMA-SPECT scans to build predictive models that can optimize dosimetry and personalize the dosage administered to each patient during the 177Lu-PSMA RPT...
The National Cancer Institute (NCI) awarded a $116,720 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to The Research Foundation for the State University of New York, Upstate Medical Center, to investigate the molecular mechanisms underlying the interaction between the intrinsically disordered protein ABL Kinase Interactor 1 (ABI1) and the Androgen Receptor (AR) in prostate cancer. The research aims to elucidate how the ABI1-AR axis regulates...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $472,458 in funding to The University of Texas Southwestern Medical Center to conduct research on overcoming therapy- and castration-resistant prostate cancer. The project aims to examine the role of the PTPN1 gene in prostate cancer transdifferentiation and develop a new theranostic strategy targeting NEPC, an end-stage prostate cancer subtype. Key objectives include...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,631,656.00 to Yale University to conduct research on the role of the UBE2J1 enzyme in regulating androgen receptor (AR) degradation and its impact on prostate cancer therapy resistance. The key objectives are to:
Analyze the effect of UBE2J1 loss on AR functions, tumor heterogeneity, and therapy resistance across multiple prostate cancer stages using in vitro and in vivo models.
Dissect the molecular mechanisms by which UBE2J1 regulates AR degradation, including identifying critical UBE2J1 domains, AR ubiquitination sites, and the responsible E3 ligase.
Evaluate the in vitro and in vivo efficacy of restoring AR degradation using PROTAC-based AR degraders in UBE2J1-deficient prostate cancer models, and assess UBE2J1 expression as a predictive biomarker for responses to AR antagonists and degraders.
The award period spans from July 2024 to August 2029, with the overarching goal of advancing the understanding of AR degradation pathways and their implications for overcoming therapy resistance in prostate cancer.